Author information

Inquiry content

Dear Sir/Madam,

Greetings from Overseas Pharmaceuticals (OPL)

I am writing to see if {xxx company} would be interested in licensing-in any of our controlled-release products.

The products are:

- Levetiracetam Extended-Release Tablets 750mg, 500mg (Reference Drug = Keppra XR [UCB])

- Ibuprofen Extended-Release Tablets 600mg (Reference Drug = Advil® 12 hour [GSK])

- Ropinirole Hydrochloride Sustained-Release Tablets 2mg (Reference Drug = Requip XL [GSK])

- Sitagliptin and Metformin HCL Extended-Release Tablets 50mg/500mg (Reference Drug = Janumet XR [Merck]

All four products are controlled-release generics of brand-name drugs approved by the US FDA. One of our products is approved by the US FDA and is on the market.

If you are interested, we also have several 505(b)(2) new formulation products in development with the furthest along product at the end of Phase III trials.

For a bit of background about the company:

OPL is a specialty pharmaceutical company focusing on the development of proprietary controlled-release technologies and the application of these technologies to develop controlled-release new drug products for product life-cycle extension. We also apply non-proprietary controlled-release technologies (e.g. single layer, bilayer, tri-layer tablet, tablet in tablet, etc.) to develop generic versions of brand-name products. OPL was founded in 2011, currently with 90+ employees and three locations.

We can also supply cutting-edge controlled-release formulation development if you have any products that would benefit from it.

We can be the initial suppliers of the product; however, we can also send our scientists to assist and facilitate the technology transfer to your facilities.

We look forward to your earliest response, and we hope we can help you add more products to your current pipeline.

Please let us know should you have any questions.

Sincerely,

Bryce Babcock